Drug Patents Expiring in 2032

1. List of Abilify Mycite Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10517507 OTSUKA Communication system with enhanced partial power source and method of manufacturing same
Jun, 2032

(9 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

2. List of Abraxane drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393318 ABRAXIS BIOSCIENCE Methods of treating cancer
Mar, 2032

(9 years from now)

US9597409 ABRAXIS BIOSCIENCE Methods of treating cancer
Mar, 2032

(9 years from now)

US9393318

(Pediatric)

ABRAXIS BIOSCIENCE Methods of treating cancer
Sep, 2032

(9 years from now)

US9597409

(Pediatric)

ABRAXIS BIOSCIENCE Methods of treating cancer
Sep, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
M Dec 6, 2022
Pediatric Exclusivity (PED) Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: Treatment of lung cancer

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's patent expiration?
More Information on Dosage

3. List of Acetadote drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8722738 CUMBERLAND PHARMS Acetycysteine compositions and methods of use thereof
Apr, 2032

(9 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ACETADOTE before it's patent expiration?
More Information on Dosage

4. List of Adzenys Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265737 NEOS THERAPS INC Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
Jun, 2032

(9 years from now)

US9017731 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(9 years from now)

US8709491 NEOS THERAPS INC Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(9 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 15 September, 2017

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage

5. List of Adzenys Xr-odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9017731 NEOS THERAPS Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(9 years from now)

US9265737 NEOS THERAPS Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
Jun, 2032

(9 years from now)

US8709491 NEOS THERAPS Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Jun, 2032

(9 years from now)

Drugs and Companies using AMPHETAMINE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

How can I launch a generic of ADZENYS XR-ODT before it's patent expiration?
More Information on Dosage

6. List of Airduo Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(8 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(8 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(9 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(9 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(9 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
M Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

7. List of Akynzeo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11312698 HELSINN HLTHCARE Fosnetupitant chloride hydrochloride having improved stability
May, 2032

(9 years from now)

US10717721 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(9 years from now)

US8426450 HELSINN HLTHCARE Substituted 4-phenyl pyridines having anti-emetic effect
May, 2032

(9 years from now)

US9908907 HELSINN HLTHCARE Substituted piperaziniums for the treatment of emesis
May, 2032

(9 years from now)

US9403772 HELSINN HLTHCARE 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895586 HELSINN HLTHCARE Methods of treating emesis
May, 2032

(9 years from now)

US10208073 HELSINN HLTHCARE Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator
May, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: April, 2022

Market Authorisation Date: 19 April, 2018

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

How can I launch a generic of AKYNZEO before it's patent expiration?
More Information on Dosage

8. List of Alecensa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9365514 HOFFMANN-LA ROCHE Composition comprising tetracyclic compound
Mar, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 6, 2024

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ALECENSA before it's patent expiration?
More Information on Dosage

9. List of Aliqopa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10383876 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
Mar, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636344 BAYER HEALTHCARE Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts
Mar, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 14, 2022
Orphan Drug Exclusivity (ODE) Sep 14, 2024

Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient

NCE-1 date: September, 2021

Market Authorisation Date: 14 September, 2017

Treatment: Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

10. List of Alkindi Sprinkle drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717740 ETON Treatment of adrenal insufficiency
Nov, 2032

(9 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Market Authorisation Date: 29 September, 2020

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

More Information on Dosage

11. List of Amvuttra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10570391 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(9 years from now)

US9399775 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 13, 2027

Drugs and Companies using VUTRISIRAN ingredient

NCE-1 date: June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

12. List of Aptiom drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9750747 SUNOVION PHARMS INC Treatments involving eslicarbazepine acetate or eslicarbazepine
Aug, 2032

(9 years from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Market Authorisation Date: 08 November, 2013

Treatment: Treatment of partial-onset seizures in a patient suffering from or susceptible to absence seizures; Treatment of partial-onset seizures

Dosage: TABLET;ORAL

How can I launch a generic of APTIOM before it's patent expiration?
More Information on Dosage

13. List of Aristada drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10226458 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Mar, 2032

(9 years from now)

US9034867 ALKERMES INC Pharmaceutical compositions comprising sorbitan esters
Nov, 2032

(9 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

14. List of Armonair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(8 years from now)

US8978966 TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(8 years from now)

US8714149 TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Feb, 2032

(9 years from now)

US10561808

(Pediatric)

TEVA PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jul, 2032

(9 years from now)

US8978966

(Pediatric)

TEVA PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jul, 2032

(9 years from now)

US8714149

(Pediatric)

TEVA PHARM Airflow adaptor for a breath-actuated dry powder inhaler
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 9, 2024
New Strength (NS) Jul 9, 2024
Pediatric Exclusivity (PED) Jan 9, 2025

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Market Authorisation Date: 27 January, 2017

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

15. List of Avycaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9284314 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US9695122 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

US8969566 ALLERGAN Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Jun, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 25, 2020
Generating Antibiotic Incentives Now (GAIN) Feb 25, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

16. List of Azstarys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9079928 COMMAVE THERAP Methylphenidate-oxoacid conjugates, processes of making and using the same
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 7, 2026

Drugs and Companies using DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 07 May, 2021

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

17. List of Belbuca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9901539 BDSI Transmucosal drug delivery devices for use in chronic pain relief
Dec, 2032

(9 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 October, 2015

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: FILM;BUCCAL

How can I launch a generic of BELBUCA before it's patent expiration?
More Information on Dosage

18. List of Bijuva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8633178 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8993549 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10052386 THERAPEUTICSMD INC Progesterone formulations
Nov, 2032

(9 years from now)

US8987237 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11166963 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8933059 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11103513 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10806740 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US9006222 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11033626 THERAPEUTICSMD INC Progesterone formulations having a desirable pk profile
Nov, 2032

(9 years from now)

US10675288 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US9114145 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US9114146 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8846648 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8846649 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10206932 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11103516 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8993548 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11110099 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10639375 THERAPEUTICSMD INC Progesterone formulations
Nov, 2032

(9 years from now)

US9301920 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 October, 2018

Treatment: Treatment of menopause symptoms, including vasomotor symptoms

Dosage: CAPSULE;ORAL

How can I launch a generic of BIJUVA before it's patent expiration?
More Information on Dosage

19. List of Bijuva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529360 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 October, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of BIJUVA before it's patent expiration?
More Information on Dosage

20. List of Biktarvy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 18, 2026
New Chemical Entity Exclusivity (NCE) Feb 7, 2023
New Patient Population (NPP) Jun 18, 2022
M Feb 24, 2024

Drugs and Companies using BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 07 February, 2018

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of BIKTARVY before it's patent expiration?
More Information on Dosage

21. List of Bortezomib drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962572 FRESENIUS KABI USA Bortezomib formulations
Nov, 2032

(9 years from now)

Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 06 November, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

22. List of Braftovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387208 ARRAY BIOPHARMA INC Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(9 years from now)

US10258622 ARRAY BIOPHARMA INC Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
Nov, 2032

(9 years from now)

US9763941 ARRAY BIOPHARMA INC Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Nov, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 27, 2023
Orphan Drug Exclusivity (ODE) Jun 27, 2025
New Indication (I) Apr 8, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; Treatment of melanoma

Dosage: CAPSULE;ORAL

How can I launch a generic of BRAFTOVI before it's patent expiration?
More Information on Dosage

23. List of Bunavail drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8703177 BDSI Abuse-resistant mucoadhesive devices for delivery of buprenorphine
Aug, 2032

(9 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: NA

Dosage: FILM;BUCCAL

How can I launch a generic of BUNAVAIL before it's patent expiration?
More Information on Dosage

24. List of Cabometyx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11298349 EXELIXIS INC Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's patent expiration?
More Information on Dosage

25. List of Caldolor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9072710 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(9 years from now)

US9072661 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
M Nov 19, 2024

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

26. List of Calquence drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

CN106243113B ASTRAZENECA As A Selective Btk Inhibitor And Pyrazine
Jul, 2032

(9 years from now)

CN103889987A ASTRAZENECA As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide
Jul, 2032

(9 years from now)

CN106243113A ASTRAZENECA Imidazole As Selective Btk Inhibitors And Paradiazine
Jul, 2032

(9 years from now)

CN103889987B ASTRAZENECA Imidazole As Selective Btk Inhibitors And Paradiazine
Jul, 2032

(9 years from now)

EP3689878B1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP3689878A1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP2734522B1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP2734522A1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 21, 2026
New Chemical Entity Exclusivity (NCE) Oct 31, 2022
New Indication (I) Nov 21, 2022

Drugs and Companies using ACALABRUTINIB ingredient

NCE-1 date: October, 2021

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia

Dosage: CAPSULE;ORAL

How can I launch a generic of CALQUENCE before it's patent expiration?
More Information on Dosage

27. List of Calquence drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

CN106243113B ASTRAZENECA As A Selective Btk Inhibitor And Pyrazine
Jul, 2032

(9 years from now)

CN103889987A ASTRAZENECA As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide
Jul, 2032

(9 years from now)

CN106243113A ASTRAZENECA Imidazole As Selective Btk Inhibitors And Paradiazine
Jul, 2032

(9 years from now)

CN103889987B ASTRAZENECA Imidazole As Selective Btk Inhibitors And Paradiazine
Jul, 2032

(9 years from now)

EP3689878B1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP3689878A1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP2734522B1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP2734522A1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(9 years from now)

US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: October, 2021

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy

Dosage: TABLET;ORAL

More Information on Dosage

28. List of Caspofungin Acetate drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636407 FRESENIUS KABI USA Caspofungin acetate formulations
Dec, 2032

(9 years from now)

Drugs and Companies using CASPOFUNGIN ACETATE ingredient

Market Authorisation Date: 30 December, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

29. List of Cetylev drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8747894 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine
May, 2032

(9 years from now)

US9561204 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine
May, 2032

(9 years from now)

US9427421 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine
May, 2032

(9 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 29 January, 2016

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: TABLET, EFFERVESCENT;ORAL

More Information on Dosage

30. List of Cometriq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11298349 EXELIXIS Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(9 years from now)

US9717720 EXELIXIS Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Feb, 2032

(9 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 29 November, 2012

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

31. List of Contrave drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248123 NALPROPION Methods of providing weight loss therapy in patients with major depression
Jan, 2032

(8 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: Use of naltrexone and bupropion for chronic weight management for treating overweight or obesity in patients with major depressive disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's patent expiration?
More Information on Dosage

32. List of Copiktra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46621 SECURA Processes for preparing isoquinolinones and solid forms of isoquinolinones
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11312718 SECURA Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
Jan, 2032

(8 years from now)

US9840505 SECURA Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof
Jan, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 24, 2023
Orphan Drug Exclusivity (ODE) Sep 24, 2025

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 24 September, 2018

Treatment: For the treatment of patients with follicular lymphoma (fl); For the treatment of patients with chronic lymphocytic leukemia (cll) and/or small lymphocytic leukemia (sll)

Dosage: CAPSULE;ORAL

More Information on Dosage

33. List of Cotempla Xr-odt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089496 NEOS THERAPS INC Compositions comprising methylphenidate complexed with ion-exchange resin particles
Jun, 2032

(9 years from now)

US9072680 NEOS THERAPS INC Compositions comprising methylphenidate complexed with ion-exchange resin particles
Jun, 2032

(9 years from now)

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 19 June, 2017

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

How can I launch a generic of COTEMPLA XR-ODT before it's patent expiration?
More Information on Dosage

34. List of Cycloset drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000522 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(9 years from now)

US8431155 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(9 years from now)

US9700555 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(9 years from now)

US9993474 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(9 years from now)

US9192576 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(9 years from now)

US8613947 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(9 years from now)

US9522117 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(9 years from now)

US10688094 VEROSCIENCE Bromocriptine formulations
Apr, 2032

(9 years from now)

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Market Authorisation Date: 05 May, 2009

Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 11; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 13 and 23; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1, 11, and 12; Adjunct to diet exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 13, 23, and 24; Improvement of glycemic control in individuals with type 2 diabetes; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 41, 52, and 53; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 66, 75, and 76; Adjunct to diet and execrise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 29, 39, and 40; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1, 13, and 14; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 54 and 64; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 29 and 39; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 13; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 66 and 75; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 41 and 52; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 89, 99, and 100; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 54, 64, and 65; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 15, 27, and 28; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 15 and 27; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 77 and 87; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 89 and 99; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 77, 87, and 88; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 43, 50 and 51; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 1,10 and 11; Adjunct to diet and excercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 30, 41, and 42; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 1 and 10; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 30 and 41; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 21 and 28; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 12 and 19; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 43 and 50; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 12, 19 and 20; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 21, 28, and 29; Administration once daily within two hours after waking in the morning for improvement of glycemic control in a type 2 diabetes patient; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 2 and 3; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 4 and 5; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 7, 8, and 9; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 1 and 2; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising bromocriptine and one or more excipients as recited in claims 4, 5, and 6; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 7 and 8; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 10 and 11; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 16, 17, and 18; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 13 and 14; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 10, 11, and 12; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 16 and 17; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 13, 14, and 15; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 28 and 29; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 25 and 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 22, 23, and 24; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 19 and 20; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 19, 20, and 21; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 28, 29, and 30; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetis by orally administering a dosage form comprising micronized bromocriptine and one or more excipients as recited in claims 25, 26, and 27

Dosage: TABLET;ORAL

More Information on Dosage

35. List of Defitelio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11085043 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(9 years from now)

US11236328 JAZZ PHARMS INC Euglobulin-based method for determining the biological activity of defibrotide
Jun, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 30, 2023

Drugs and Companies using DEFIBROTIDE SODIUM ingredient

Market Authorisation Date: 30 March, 2016

Treatment: Treatment of adult and pediatric patients with hepatic veno-occlusive disease (vod), also known as sinusoidal obstruction syndrome (sos), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (hsct)

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

36. List of Descovy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2024
New Indication (I) Oct 3, 2022

Drugs and Companies using EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 04 April, 2016

Treatment: Prophylaxis of hiv-1 infection; Treatment of hiv-1 infection; Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of DESCOVY before it's patent expiration?
More Information on Dosage

37. List of Detectnet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10159759 RADIOMEDIX Pet tracer for imaging of neuroendocrine tumors
Aug, 2032

(9 years from now)

US10383961 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(9 years from now)

US11160888 RADIOMEDIX PET tracer for imaging of neuroendocrine tumors
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 3, 2025
Orphan Drug Exclusivity (ODE) Sep 3, 2027

Drugs and Companies using COPPER DOTATATE CU-64 ingredient

NCE-1 date: September, 2024

Market Authorisation Date: 03 September, 2020

Treatment: Use of cu-64 dotatate with positron emission tomography (pet) for localization of somatostatin receptor positive neuroendocrine tumors (nets) in adult patients

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

38. List of Dexilant drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9233103 TAKEDA PHARMS USA Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
Mar, 2032

(9 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's patent expiration?
More Information on Dosage

39. List of Dexycu Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799642 EYEPOINT PHARMS Dose guides for injection syringe
May, 2032

(9 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 09 February, 2018

Treatment: NA

Dosage: SUSPENSION;INTRAOCULAR

More Information on Dosage

40. List of Dilaudid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731082 FRESENIUS KABI USA Drug container
Apr, 2032

(9 years from now)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 11 January, 1984

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DILAUDID before it's patent expiration?
More Information on Dosage

41. List of Duzallo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8546436 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Feb, 2032

(9 years from now)

Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

42. List of Epaned Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9855214 SILVERGATE PHARMS Enalapril compositions
Nov, 2032

(9 years from now)

US9968553 SILVERGATE PHARMS Enalapril compositions
Nov, 2032

(9 years from now)

US8778366 SILVERGATE PHARMS Enalapril compositions
Nov, 2032

(9 years from now)

US8568747 SILVERGATE PHARMS Enalapril compositions
Nov, 2032

(9 years from now)

Drugs and Companies using ENALAPRIL MALEATE ingredient

Market Authorisation Date: 13 August, 2013

Treatment: Method of treatment of heart failure; Treatment of hypertension; Method of treating left ventricular dysfunction; Method of treating hypertension; Treatment of heart failure

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of EPANED KIT before it's patent expiration?
More Information on Dosage

43. List of Epclusa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8940718 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8575135 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

US8921341 GILEAD SCIENCES INC Antiviral compounds
Nov, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 10, 2028
M Apr 27, 2025
Pediatric Exclusivity (PED) Dec 10, 2028

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 10 June, 2021

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

More Information on Dosage

44. List of Epsolay drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687465 GALDERMA LABS LP Compositions for the treatment of rosacea
Nov, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 22, 2025

Drugs and Companies using BENZOYL PEROXIDE ingredient

Market Authorisation Date: 22 April, 2022

Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage

45. List of Evotaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 BRISTOL-MYERS SQUIBB Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

Drugs and Companies using ATAZANAVIR SULFATE; COBICISTAT ingredient

Market Authorisation Date: 29 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of EVOTAZ before it's patent expiration?
More Information on Dosage

46. List of Evzio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8627816 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2032

(9 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2014

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

47. List of Evzio (autoinjector) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8627816 KALEO INC Medicament delivery device for administration of opioid antagonists including formulations for naloxone
Feb, 2032

(9 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 October, 2016

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

48. List of Fetzima drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8865937 ALLERGAN Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
May, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
M Oct 7, 2022

Drugs and Companies using LEVOMILNACIPRAN HYDROCHLORIDE ingredient

Market Authorisation Date: 25 July, 2013

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of FETZIMA before it's patent expiration?
More Information on Dosage

49. List of Firdapse drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11268128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US11274332 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US11274331 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

US11060128 CATALYST PHARMS Methods of administering 3,4-diaminopyridine
Jun, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 28, 2023
Orphan Drug Exclusivity (ODE) Nov 28, 2025
New Patient Population (NPP) Sep 29, 2025

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

NCE-1 date: November, 2022

Market Authorisation Date: 28 November, 2018

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

More Information on Dosage

50. List of Firmagon drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415085 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(9 years from now)

US10695398 FERRING Method of treating prostate cancer with GnRH antagonist
Apr, 2032

(9 years from now)

Drugs and Companies using DEGARELIX ACETATE ingredient

Market Authorisation Date: 24 December, 2008

Treatment: Method of treating prostate cancer

Dosage: POWDER;SUBCUTANEOUS

How can I launch a generic of FIRMAGON before it's patent expiration?
More Information on Dosage

51. List of Genvoya drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 05 November, 2015

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

More Information on Dosage

52. List of Gilenya drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592208 NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Mar, 2032

(9 years from now)

US9592208

(Pediatric)

NOVARTIS Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Sep, 2032

(9 years from now)

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

Market Authorisation Date: 21 September, 2010

Treatment: Treatment of multiple sclerosis in the pediatric patient population with 0.25 mg fingolimod

Dosage: CAPSULE;ORAL

How can I launch a generic of GILENYA before it's patent expiration?
More Information on Dosage

53. List of Gonitro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101592 POHL BOSKAMP Stabilized granules containing glyceryl trinitrate
Mar, 2032

(9 years from now)

Drugs and Companies using NITROGLYCERIN ingredient

Market Authorisation Date: 08 June, 2016

Treatment: NA

Dosage: POWDER;SUBLINGUAL

More Information on Dosage

54. List of Harvoni drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9393256 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(9 years from now)

US10456414 GILEAD SCIENCES INC Methods for treating HCV
Sep, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Dosing Schedule (D) Nov 15, 2022
Orphan Drug Exclusivity (ODE) Apr 7, 2024
Pediatric Exclusivity (PED) Oct 7, 2024

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 10 October, 2014

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage

55. List of Ilevro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921337 NOVARTIS Carboxyvinyl polymer-containing nanoparticle suspensions
Mar, 2032

(9 years from now)

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 16 October, 2012

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

How can I launch a generic of ILEVRO before it's patent expiration?
More Information on Dosage

56. List of Imvexxy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537581 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US11246875 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US11241445 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US10835487 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US9289382 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US10806697 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US11351182 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US11304959 THERAPEUTICSMD INC Vaginal inserted estradiol pharmaceutical compositions and methods
Nov, 2032

(9 years from now)

US11497709 THERAPEUTICSMD INC NA
Nov, 2032

(9 years from now)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 May, 2018

Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy

Dosage: INSERT;VAGINAL

How can I launch a generic of IMVEXXY before it's patent expiration?
More Information on Dosage

57. List of Inbrija drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945612 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(9 years from now)

US8685442 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(9 years from now)

US8545878 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(9 years from now)

US9393210 ACORDA Capsules containing high doses of levodopa for pulmonary use
Nov, 2032

(9 years from now)

Drugs and Companies using LEVODOPA ingredient

Market Authorisation Date: 21 December, 2018

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

58. List of Inrebic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10391094 IMPACT Compositions and methods for treating myelofibrosis
Jun, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 16, 2026
New Chemical Entity Exclusivity (NCE) Aug 16, 2024

Drugs and Companies using FEDRATINIB HYDROCHLORIDE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 16 August, 2019

Treatment: Treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis

Dosage: CAPSULE;ORAL

More Information on Dosage

59. List of Ionsys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8781571 THE MEDICINES CO Switch validation circuit and method
Mar, 2032

(9 years from now)

US8428708 THE MEDICINES CO Self-test for analgesic product
May, 2032

(9 years from now)

US8428709 THE MEDICINES CO Current control for electrotransport drug delivery
Jun, 2032

(9 years from now)

Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: Method for iontophoretic transdermal delivery of fentanyl hydrochloride

Dosage: SYSTEM;IONTOPHORESIS, TRANSDERMAL

More Information on Dosage

60. List of Isentress drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10772888 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Mar, 2032

(9 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 12 October, 2007

Treatment: Treatment of hiv-1 infection

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS before it's patent expiration?
More Information on Dosage

61. List of Jornay Pm drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241392 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10905652 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10182995 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US8927010 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9023389 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9283214 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9498447 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US11241391 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10881618 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10617651 IRONSHORE PHARMS Compositions for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US10292937 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9603809 IRONSHORE PHARMS Methods of treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US8916588 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9034902 IRONSHORE PHARMS Methods for treatment of attention deficit hyperactivity disorder
Mar, 2032

(9 years from now)

US9028868 IRONSHORE PHARMS Methods and compositions for treatment of attention deficit disorder
Mar, 2032

(9 years from now)

Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 August, 2018

Treatment: Method of treating attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

62. List of Korlym drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842801 CORCEPT THERAP Optimizing mifepristone absorption
Nov, 2032

(9 years from now)

Drugs and Companies using MIFEPRISTONE ingredient

Market Authorisation Date: 17 February, 2012

Treatment: Treating cushing's syndrome

Dosage: TABLET;ORAL

How can I launch a generic of KORLYM before it's patent expiration?
More Information on Dosage

63. List of Kuvan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9216178 BIOMARIN PHARM Dry blend formulation of tetrahydrobiopterin
Nov, 2032

(9 years from now)

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2013

Treatment: NA

Dosage: POWDER;ORAL

How can I launch a generic of KUVAN before it's patent expiration?
More Information on Dosage

64. List of Lazanda drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731869 BTCP PHARMA Container
Jan, 2032

(8 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 30 June, 2011

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

65. List of Levothyroxine Sodium drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168238 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(9 years from now)

US9168239 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(9 years from now)

US9006289 FRESENIUS KABI USA Levothyroxine formulations
Oct, 2032

(9 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 24 June, 2011

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of LEVOTHYROXINE SODIUM before it's patent expiration?
More Information on Dosage

66. List of Livmarli drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11376251 MIRUM Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Oct, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 29, 2026
Orphan Drug Exclusivity (ODE) Sep 29, 2028

Drugs and Companies using MARALIXIBAT CHLORIDE ingredient

NCE-1 date: September, 2025

Market Authorisation Date: 29 September, 2021

Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)

Dosage: SOLUTION;ORAL

More Information on Dosage

67. List of Lokelma drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11406662 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US10413569 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US8802152 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8808750 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US9844567 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US9861658 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US10335432 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

US10398730 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 18, 2023
M Apr 24, 2023

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 18 May, 2018

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of LOKELMA before it's patent expiration?
More Information on Dosage

68. List of Lonhala Magnair Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168556 SUNOVION RESP Membrane nebulizer and method for welding a membrane to a carrier during the production of a membrane nebulizer
Sep, 2032

(9 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage

69. List of Lybalvi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778960 ALKERMES INC Methods for treating antipsychotic-induced weight gain
Feb, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 28, 2026

Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient

NCE-1 date: May, 2025

Market Authorisation Date: 28 May, 2021

Treatment: Method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain

Dosage: TABLET;ORAL

More Information on Dosage

70. List of Mavyret drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648037 ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jan, 2032

(8 years from now)

US8937150 ABBVIE INC Anti-viral compounds
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648037

(Pediatric)

ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jul, 2032

(9 years from now)

US8937150

(Pediatric)

ABBVIE INC Anti-viral compounds
Nov, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 3, 2022
M Apr 10, 2023
New Dosing Schedule (D) Sep 26, 2022
Orphan Drug Exclusivity (ODE) Jun 10, 2028
Pediatric Exclusivity (PED) Mar 26, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: March, 2022

Market Authorisation Date: 10 June, 2021

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg

Dosage: PELLETS;ORAL

More Information on Dosage

71. List of Mekinist drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399021 NOVARTIS Pharmaceutical composition
Jan, 2032

(8 years from now)

US9271941 NOVARTIS Pharmaceutical composition
Jan, 2032

(8 years from now)

US9155706 NOVARTIS Pharmaceutical composition
Jan, 2032

(8 years from now)

US8580304 NOVARTIS Pharmaceutical composition
Jan, 2032

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 22, 2024
M Oct 6, 2022
New Indication (I) Jun 22, 2025

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Market Authorisation Date: 29 May, 2013

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

72. List of Movantik drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9012469 REDHILL Crystalline naloxol-peg conjugate
Apr, 2032

(9 years from now)

Drugs and Companies using NALOXEGOL OXALATE ingredient

Market Authorisation Date: 16 September, 2014

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of MOVANTIK before it's patent expiration?
More Information on Dosage

73. List of Neoprofen drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415337 RECORDATI RARE Ibuprofen compositions and methods of making same
Mar, 2032

(9 years from now)

Drugs and Companies using IBUPROFEN LYSINE ingredient

Market Authorisation Date: 13 April, 2006

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of NEOPROFEN before it's patent expiration?
More Information on Dosage

74. List of Netspot drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9375498 AAA USA INC Process for the preparation of complexes of 68Ga
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 1, 2023

Drugs and Companies using GALLIUM DOTATATE GA-68 ingredient

Market Authorisation Date: 01 June, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

75. List of Neupro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925150 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Mar, 2032

(9 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Market Authorisation Date: 09 May, 2007

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of NEUPRO before it's patent expiration?
More Information on Dosage

76. List of Nuvessa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9198858 CHEMO RESEARCH SL Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations
Jun, 2032

(9 years from now)

US8946276 CHEMO RESEARCH SL High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
Jun, 2032

(9 years from now)

US10596155 CHEMO RESEARCH SL Aqueous-based metronidazole gel formulations
Jun, 2032

(9 years from now)

US10238634 CHEMO RESEARCH SL Aqueous-based metronidazole gel formulations
Jun, 2032

(9 years from now)

Drugs and Companies using METRONIDAZOLE ingredient

Market Authorisation Date: 24 March, 2014

Treatment: Treatment of bacterial vaginosis with metronidazole gel

Dosage: GEL;VAGINAL

How can I launch a generic of NUVESSA before it's patent expiration?
More Information on Dosage

77. List of Odefsey drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

Drugs and Companies using EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 01 March, 2016

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of ODEFSEY before it's patent expiration?
More Information on Dosage

78. List of Ofirmev drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9399012

(Pediatric)

MALLINCKRODT HOSP Reduced dose intravenous acetaminophen
Mar, 2032

(9 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 02 November, 2010

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of OFIRMEV before it's patent expiration?
More Information on Dosage

79. List of Olinvyk drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11077098 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

US9309234 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

US8835488 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9642842 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 30, 2025

Drugs and Companies using OLICERIDINE ingredient

NCE-1 date: October, 2024

Market Authorisation Date: 30 October, 2020

Treatment: Management of acute pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

80. List of Olumiant drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089574 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
Nov, 2032

(9 years from now)

US11045474 ELI LILLY AND CO Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections
Nov, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) May 10, 2025
New Chemical Entity Exclusivity (NCE) May 31, 2023

Drugs and Companies using BARICITINIB ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo)

Dosage: TABLET;ORAL

How can I launch a generic of OLUMIANT before it's patent expiration?
More Information on Dosage

81. List of Ongentys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9630955 NEUROCRINE Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor
Dec, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 24 April, 2020

Treatment: Method of treating parkinson's disease

Dosage: CAPSULE;ORAL

More Information on Dosage

82. List of Oxbryta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10034879 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(9 years from now)

US10806733 GLOBAL BLOOD THERAPS Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Dec, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10017491 GLOBAL BLOOD THERAPS Compounds and uses thereof for the modulation of hemoglobin
Dec, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 25, 2024

Drugs and Companies using VOXELOTOR ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 17 December, 2021

Treatment: NA

Dosage: TABLET, FOR SUSPENSION;ORAL

More Information on Dosage

83. List of Ozempic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Jan 16, 2023
New Chemical Entity Exclusivity (NCE) Dec 5, 2022
New Dosing Schedule (D) Mar 28, 2025

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of OZEMPIC before it's patent expiration?
More Information on Dosage

84. List of Pataday Once Daily Relief drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791154 ALCON LABS INC High concentration olopatadine ophthalmic composition
May, 2032

(9 years from now)

US9533053 ALCON LABS INC High concentration olopatadine ophthalmic composition
May, 2032

(9 years from now)

Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 2015

Treatment: Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of PATADAY ONCE DAILY RELIEF before it's patent expiration?
More Information on Dosage

85. List of Pepaxto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10285946 ONCOPEPTIDES AB Lyophilized preparations of melphalan flufenamide
Apr, 2032

(9 years from now)

US11344622 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(9 years from now)

US10543274 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(9 years from now)

US10322182 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(9 years from now)

US10869928 ONCOPEPTIDES AB Lyophilized preparation of cytotoxic dipeptides
Apr, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 26, 2028
New Chemical Entity Exclusivity (NCE) Feb 26, 2026

Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient

NCE-1 date: February, 2025

Market Authorisation Date: 26 February, 2021

Treatment: In combination with dexamethasone to treat relapsed or refactory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received at least 4 prior lines of therapy

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

86. List of Plenvu drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529368 SALIX Colonoscopy—preparation
Mar, 2032

(9 years from now)

US10780112 SALIX Colonoscopy-preparation
Mar, 2032

(9 years from now)

US10792306 SALIX Colonoscopy—preparation
Mar, 2032

(9 years from now)

US10646512 SALIX Colonoscopy - preparation
Mar, 2032

(9 years from now)

US9592252 SALIX Colonoscopy—preparation
Aug, 2032

(9 years from now)

Drugs and Companies using ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE ingredient

Market Authorisation Date: 04 May, 2018

Treatment: For cleansing of the colon in preparation for colonoscopy in adults

Dosage: FOR SOLUTION;ORAL

How can I launch a generic of PLENVU before it's patent expiration?
More Information on Dosage

87. List of Ponvory drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9062014 JANSSEN PHARMS Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one
May, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 18, 2026

Drugs and Companies using PONESIMOD ingredient

NCE-1 date: March, 2025

Market Authorisation Date: 18 March, 2021

Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

Dosage: TABLET;ORAL

More Information on Dosage

88. List of Precedex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338470 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US8455527 HOSPIRA Methods of treatment using a dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US8648106 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US9616049 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US8242158 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US10016396 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US9320712 HOSPIRA Dexmedetomidine premix formulation
Jan, 2032

(8 years from now)

US8455527

(Pediatric)

HOSPIRA Methods of treatment using a dexmedetomidine premix formulation
Jul, 2032

(9 years from now)

US8338470

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(9 years from now)

US9320712

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(9 years from now)

US9616049

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(9 years from now)

US8242158

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(9 years from now)

US8648106

(Pediatric)

HOSPIRA Dexmedetomidine premix formulation
Jul, 2032

(9 years from now)

Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 December, 1999

Treatment: Use for sedation

Dosage: INJECTABLE;INJECTION

How can I launch a generic of PRECEDEX before it's patent expiration?
More Information on Dosage

89. List of Prezcobix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 JANSSEN PRODS Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR ingredient

Market Authorisation Date: 29 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of PREZCOBIX before it's patent expiration?
More Information on Dosage

90. List of Proair Digihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(8 years from now)

US8978966 TEVA BRANDED PHARM Dose counters for inhalers, inhalers and methods of assembly thereof
Jan, 2032

(8 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 31 March, 2015

Treatment: NA

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

91. List of Proair Hfa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(8 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 29 October, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of PROAIR HFA before it's patent expiration?
More Information on Dosage

92. List of Prolensa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10085958 BAUSCH AND LOMB Bromfenac bioavailability
Nov, 2032

(9 years from now)

Drugs and Companies using BROMFENAC SODIUM ingredient

Market Authorisation Date: 05 April, 2013

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of PROLENSA before it's patent expiration?
More Information on Dosage

93. List of Pyrukynd drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682080 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(9 years from now)

US10632114 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(9 years from now)

US9980961 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(9 years from now)

US9193701 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
Oct, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 17, 2027

Drugs and Companies using MITAPIVAT SULFATE ingredient

NCE-1 date: February, 2026

Market Authorisation Date: 17 February, 2022

Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency

Dosage: TABLET;ORAL

More Information on Dosage

94. List of Qinlock drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8461179 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jun, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48731 DECIPHERA PHARMS Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
Jun, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 15, 2025
Orphan Drug Exclusivity (ODE) May 15, 2027

Drugs and Companies using RIPRETINIB ingredient

NCE-1 date: May, 2024

Market Authorisation Date: 15 May, 2020

Treatment: Treatment of gastrointestinal stromal tumor

Dosage: TABLET;ORAL

More Information on Dosage

95. List of Qulipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754096 ABBVIE INC Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 28, 2026

Drugs and Companies using ATOGEPANT ingredient

NCE-1 date: September, 2025

Market Authorisation Date: 28 September, 2021

Treatment: Preventive treatment of episodic migraine in adults

Dosage: TABLET;ORAL

More Information on Dosage

96. List of Qvar 40 drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 TEVA BRANDED PHARM Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(8 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 15 September, 2000

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of QVAR 40 before it's patent expiration?
More Information on Dosage

97. List of Qvar Redihaler drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 NORTON WATERFORD Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(8 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Market Authorisation Date: 03 August, 2017

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

98. List of Ravicti drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9326966 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs
Mar, 2032

(9 years from now)

US8404215 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging
Mar, 2032

(9 years from now)

US9095559 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs
Mar, 2032

(9 years from now)

US9254278 HORIZON THERAP Methods of therapeutic monitoring of nitrogen scavenging drugs
Mar, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 28, 2024

Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient

Market Authorisation Date: 01 February, 2013

Treatment: Treatment of a urea cycle disorder; Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder

Dosage: LIQUID;ORAL

How can I launch a generic of RAVICTI before it's patent expiration?
More Information on Dosage

99. List of Restasis drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8561859 ALLERGAN Dispensing device
Apr, 2032

(9 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 December, 2002

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

How can I launch a generic of RESTASIS before it's patent expiration?
More Information on Dosage

100. List of Rexulti drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10307419 OTSUKA Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof
Oct, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Dec 27, 2024

Drugs and Companies using BREXPIPRAZOLE ingredient

Market Authorisation Date: 10 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of REXULTI before it's patent expiration?
More Information on Dosage

101. List of Saxenda drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(9 years from now)

US9132239

(Pediatric)

NOVO Dial-down mechanism for wind-up pen
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Dec 4, 2023

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 23 December, 2014

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of SAXENDA before it's patent expiration?
More Information on Dosage

102. List of Sinuva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8763222 INTERSECT ENT INC Methods and devices for crimping self-expanding devices
Feb, 2032

(9 years from now)

Drugs and Companies using MOMETASONE FUROATE ingredient

Market Authorisation Date: 08 December, 2017

Treatment: NA

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

103. List of Stivarga drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9957232 BAYER HLTHCARE 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 27, 2024

Drugs and Companies using REGORAFENIB ingredient

Market Authorisation Date: 27 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of STIVARGA before it's patent expiration?
More Information on Dosage

104. List of Stribild drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 27 August, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of STRIBILD before it's patent expiration?
More Information on Dosage

105. List of Sublocade drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921387 INDIVIOR INC Injectable flowable composition comprising buprenorphine
Jan, 2032

(8 years from now)

Drugs and Companies using BUPRENORPHINE ingredient

Market Authorisation Date: 30 November, 2017

Treatment: Treating opioid dependency by administering buprenorphine once per month; Treating opioid dependence by administering buprenorphine

Dosage: SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

106. List of Symtuza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754065 JANSSEN PRODS Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

US9296769 JANSSEN PRODS Tenofovir alafenamide hemifumarate
Aug, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 JANSSEN PRODS Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

Drugs and Companies using COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 17 July, 2018

Treatment: Treatment of hiv-1 infection in adults who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months; Treatment of hiv-1 infection in adults and pediatric patients weighing at least 40 kg who have no prior antiretroviral treatment history or are virologically suppressed on a stable antiretroviral regimen for at least 6 months

Dosage: TABLET;ORAL

How can I launch a generic of SYMTUZA before it's patent expiration?
More Information on Dosage

107. List of Synjardy Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(9 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 09 December, 2016

Treatment: Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin; Treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of SYNJARDY XR before it's patent expiration?
More Information on Dosage

108. List of Tagrisso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11524951 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(9 years from now)

US9732058 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(9 years from now)

US8946235 ASTRAZENECA 2-(2,4,5-substituted-anilino) pyrimidine compounds
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 18, 2027
New Indication (I) Dec 18, 2023

Drugs and Companies using OSIMERTINIB MESYLATE ingredient

Market Authorisation Date: 13 November, 2015

Treatment: Treatment of patients with metastatic epidermal growth factor receptor (egfr) t790m mutation-positive non-small cell lung cancer (nsclc), who have progressed on or after egfr tki therapy; Treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21l858r mutations; Adjuvant therapy after tumor resection in patients with non-small cell lung cancer(nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19deletions or exon 21 l858r mutations

Dosage: TABLET;ORAL

How can I launch a generic of TAGRISSO before it's patent expiration?
More Information on Dosage

109. List of Tasigna drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9061029 NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9061029

(Pediatric)

NOVARTIS Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
Oct, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 23, 2028
Pediatric Exclusivity (PED) Sep 22, 2025

Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 29 October, 2007

Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml); Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml) by administering nilotinib dispersed in a fruit preparation

Dosage: CAPSULE;ORAL

How can I launch a generic of TASIGNA before it's patent expiration?
More Information on Dosage

110. List of Tavalisse drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8771648 RIGEL PHARMS INC (Trimethoxyphenylamino) pyrimidinyl formulations
Jul, 2032

(9 years from now)

US8951504 RIGEL PHARMS INC (trimethoxyphenylamino) pyrimidinyl formulations
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 17, 2025
New Chemical Entity Exclusivity (NCE) Apr 17, 2023

Drugs and Companies using FOSTAMATINIB DISODIUM ingredient

NCE-1 date: April, 2022

Market Authorisation Date: 17 April, 2018

Treatment: Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (itp) who have had an insufficient response to a previous treatment

Dosage: TABLET;ORAL

How can I launch a generic of TAVALISSE before it's patent expiration?
More Information on Dosage

111. List of Tazverik drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11052093 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US9090562 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522152 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US9855275 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US8765732 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US10155002 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US9549931 EPIZYME INC Aryl- or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

US10420775 EPIZYME INC Aryl-or heteroaryl-substituted benzene compounds
Apr, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 23, 2025
New Indication (I) Jun 18, 2023
Orphan Drug Exclusivity (ODE) Jan 23, 2027

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

NCE-1 date: January, 2024

Market Authorisation Date: 23 January, 2020

Treatment: Method of treating a lung metastasis of epithelioid sarcoma; Method of treating epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma positive for an enhancer of zeste homolog 2 (ezh2) mutation; Method of treating relapsed or refractory follicular lymphoma; Method of treating follicular lymphoma

Dosage: TABLET;ORAL

More Information on Dosage

112. List of Technivie drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient

Market Authorisation Date: 24 July, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

113. List of Torisel drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791097 PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer
May, 2032

(9 years from now)

US8791097

(Pediatric)

PF PRISM CV Anti-tumor activity of CCI-779 in papillary renal cell cancer
Nov, 2032

(9 years from now)

Drugs and Companies using TEMSIROLIMUS ingredient

Market Authorisation Date: 30 May, 2007

Treatment: Method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; Method of treating metastatic papillary renal cell carcinoma with temsirolimus.

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of TORISEL before it's patent expiration?
More Information on Dosage

114. List of Trijardy Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(9 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 January, 2020

Treatment: Treatment of a treatment-naive patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprisingmetformin and an outer coating comprising empagliflozin and linagliptin; Treatment of a type 2 diabetes mellitus patient with insufficient glycemic control despite metformin therapy using a composition comprising an extended release core comprising metformin and an outer coating comprising empagliflozin and linagliptin

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of TRIJARDY XR before it's patent expiration?
More Information on Dosage

115. List of Trintellix drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278096 TAKEDA PHARMS USA Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
Mar, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
M Jan 22, 2024

Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient

Market Authorisation Date: 30 September, 2013

Treatment: Use in the treatment of major depressive disorder to improve treatment emergent sexual dysfunction (tesd) induced by prior serotonin reuptake inhibitor treatment

Dosage: TABLET;ORAL

How can I launch a generic of TRINTELLIX before it's patent expiration?
More Information on Dosage

116. List of Trudhesa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550036 IMPEL NEUROPHARMA Nasal drug delivery device
Sep, 2032

(9 years from now)

US10507295 IMPEL NEUROPHARMA Nasal drug delivery device
Dec, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 2, 2024

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Market Authorisation Date: 02 September, 2021

Treatment: NA

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

117. List of Trulance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11319346 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Mar, 2032

(9 years from now)

US9616097 SALIX Formulations of guanylate cyclase C agonists and methods of use
Aug, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 19, 2022

Drugs and Companies using PLECANATIDE ingredient

NCE-1 date: January, 2021

Market Authorisation Date: 19 January, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TRULANCE before it's patent expiration?
More Information on Dosage

118. List of Tukysa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9457093 SEAGEN Solid dispersions of a ERB2 (HER2) inhibitor
Oct, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 17, 2027
New Chemical Entity Exclusivity (NCE) Apr 17, 2025

Drugs and Companies using TUCATINIB ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 17 April, 2020

Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

119. List of Tuxarin Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066942 MAINPOINTE Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
Jan, 2032

(8 years from now)

US9107921 MAINPOINTE Oral dosage forms for oxygen containing active agents and oxyl-containing polymers
Jan, 2032

(8 years from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE ingredient

Market Authorisation Date: 22 June, 2015

Treatment: Treatment of cough and symptoms associated with upper respiratory allergies or a common cold with codeine phosphate and chlorpheniramine maleate orally administered extended release tablets

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

120. List of Tybost drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039718 GILEAD SCIENCES INC Use of solid carrier particles to improve the processability of a pharmaceutical agent
Oct, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 22, 2026
New Patient Population (NPP) Aug 22, 2022

Drugs and Companies using COBICISTAT ingredient

Market Authorisation Date: 24 September, 2014

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of TYBOST before it's patent expiration?
More Information on Dosage

121. List of Ubrelvy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754096 ALLERGAN Piperidinone carboxamide azaindane CGRP receptor antagonists
Jul, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 23, 2024

Drugs and Companies using UBROGEPANT ingredient

NCE-1 date: December, 2023

Market Authorisation Date: 23 December, 2019

Treatment: Acute treatment of migraine with headache, with or without aura in adults

Dosage: TABLET;ORAL

More Information on Dosage